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dominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and
para-aortic lymph node dissection, omentectomy, and appendectomy,
followed by six cycles of carboplatin/paclitaxel, pelvic radiation, and
vaginal brachytherapy. She was monitored with serial CT images of
the chest/abdomen/pelvis and CA-125 levels. Imaging in April 2013
was negative and CA-125 level was 26 units/mL in May 2013. She
then immigrated to the US.
On June 2013, the patient presented to the emergency room withIntroduction
While endometrial cancer is themost common gynecological cancer
with a generally favorable prognosis, the histological subtype of serous
carcinoma is more aggressive and fortunately uncommon. Uterine se-
rous carcinoma (USC) accounts for about 10% of cases of endometrial
cancer and yet 39% of its deaths (Boruta et al., 2009). Brain metastasis
from endometrial cancer is also rare, with a rate of 0.6% from a review
of over 10,000 patients (Piura and Piura, 2012). This recent review of
35 studies by Piura et al. identiﬁed 115 cases of endometrial cancer
that metastasized to the brain, of which 4 were USC (Piura and Piura,
2012). A further review of the literature uncovered an additional 4
cases. Here we present a new case from our institution, review the
existing literature, and discuss current treatment options.
Case report
The patient is a 55 year-old woman G1P1001 with no signiﬁcant
medical history who was diagnosed with stage IIIC2 USC in Cartagena,
Spain. She initially presented with postmenopausal bleeding and pelvic
fullness. A CT scan was consistent with an endometrial and left adnexal
solid mass, retroperitoneal lymphadenopathy, mild ascites, grades I–II
ureterohydronephrosis, and nonspeciﬁc pulmonary micronodules. Lab-
oratory studies revealed an elevated CA-125 level of 121 units/mL. Sub-
sequent MRI suggested that the mass invaded greater than 50% of therra), long.nguyen@mssm.edu
elli), tamara.kalir@mssm.edu
. This is an open access article underheadache and dizziness of 3 days duration. She also reported an episode
of urinary incontinence and near-syncope but denied any other focal
neurological deﬁcits. Her neurological exam was normal. A head CT
scan revealed signiﬁcant bifrontal edemawith suggestion of an underly-
ing lesion. AnMRI demonstrated a well-circumscribed heterogeneously
enhancingmass involving the anterior body of the corpus callosum and
extending superiorly to the falx cerebri, measuring 3.6 × 4.1 cm (Fig. 1).
Her CA-125 level was 107 units/mL. A CT of the chest, abdomen and pel-
vis was negative for metastatic disease.
Later that month, she underwent a bifrontal craniotomy and tumor
resection via right sided para-falcine approach. Histology revealed cere-
bral metastasis from serous carcinoma with immunohistochemistry pro-
ﬁle (CK7+, CK8/18+, CK20−, CDX2−, BRST2−, TTF1−) consistent
with primary endometrial carcinoma (Fig. 2). Postoperatively, she devel-
oped bilateral pulmonary emboli with a saddle embolism component.
The patient was subsequently evaluated for consolidative whole
brain radiation (WBRT) vs. stereotactic radiosurgery (SRS) to the post-
operative cavity and residual tumor. Due to the size of the postoperative
bed, as well as rapid interval post-surgical growth, she was givenWBRT
followed by chemotherapy (gemcitabine and carboplatin). Residual
tumorwas left attached to the corpus callosum and pericallosal arteries,
as it was thought that aggressive resection of this portion would carry a
high risk of post-surgical neurologic morbidity; however about 20 days
later, reimaging suggested a continued growth of the residual tumor
posteriorly along the corpus callosum and superiorly into the frontal
lobes. In February 2014, imaging revealed metastatic lung nodules. As
of submission date, she is alive with disease on chemotherapy.Discussion
USC is an uncommon form of endometrial cancer that rarely metas-
tasizes to the brain. Herein we present a summary of the eight reported
cases in the literature; our case report marks the ninth. An extraction ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Preoperative sagittal MRI with IV contrast showing enhancing mass involving the
anterior body of the corpus callosum.
35T. Sierra et al. / Gynecologic Oncology Reports 11 (2015) 34–37clinicopathological features (age, stage, grade, lymphovascular space in-
volvement), time interval to brainmetastasis, diagnosticﬁndings (num-
ber and location of brain metastases, presence of systemic disease),
treatment, and survival is summarized in Table 1 (Petru et al., 2001;
Gulsen and Terzi, 2013; Chura JC et al., n.d.; Gien et al., 2004; Talwar
and Cohen, 2012; Dietrich et al., 2005; Comert et al., 2012).
Among the nine cases of USCmetastatic to the brain, themedian age
was 69.5 with a median survival of 5 months since diagnosis of brain
metastasis. Our case report is the youngest patient at 55 and she is
still alive at 12 months, currently undergoing treatment.Fig. 2. (A)Microscopic low-power view showing brain parenchyma inﬁltrated by carcinoma and
glandular structures and a pseudopapillary arrangement of the tumor cells (H&E, ×200). (C)
mitotic ﬁgure (blue arrow, H&E, ×400). (D) Tumor cells with positive cytokeratin-7 immunohThe stages of USC were varied, with 4 stage I, 3 stage III, 1 unstaged,
and 1 unreported stage. This variation translated into a large interval of
diagnosis of brain metastasis from USC, with a median interval of 23
months (range, 0.6 months to greater than 5 years). This is consistent
with the previous ﬁnding of a median of 17 months (range, 2 to 108
months) for all endometrial carcinoma (Piura and Piura, 2012).
Most of the cancers were high-grade with N50% myometrial inva-
sion and signs of systemic disease at the time of brain metastasis (al-
though 3 cases showed no other sites of metastases). This ﬁnding is
also similar to Piura et al.'s conclusion that 80% of patients who devel-
oped brain metastases from endometrial carcinoma presented with
high-grade disease and about half had disseminated disease, although
certainly our case series yields far too few numbers to state any deﬁni-
tive conclusions (Piura and Piura, 2012).
The quantity and location of lesions in the nine cases reviewed var-
ied considerably. A third of brainmetastatic lesionswere solitary, a third
were multiple, and a third were unreported. Given that the route of
spread is primarily hematological when metastatic to the brain, the le-
sions demonstrated wide spatial distribution.
The treatments for brainmetastasis include:WBRT, excisional surgery
(i.e. craniotomy), radiosurgery, and chemotherapy. While metastatic
brain tumors are the most common intracranial tumor (typically from
the lung, breast, renal, and gastrointestinal cancers), treatment varies ac-
cording to lesion number, accessibility, and overall prognosis. There is no
standard of care for USC brain metastasis given the paucity of cases, al-
though general principles fromneurosurgerymay be followed. Tradition-
ally, solitary brain lesions would undergo resection followed by WBRT
and multiple lesions would receive WBRT (Piura and Piura, 2012). In
the present case series, 3 patients underwent surgical resection (1 with
a solitary lesion, 1 resected one of three lesions that was causingmass ef-
fect, and 1 unspeciﬁed lesion) (Petru et al., 2001; Gulsen and Terzi, 2013;
Chura JC et al., n.d.). Only 1 patient underwent radiosurgery as part of
multimodal therapy and 5 patients underwent WBRT.
Chemotherapeutic regimens for brain metastasis are difﬁcult to se-
lect because of the paucity of data for endometrial cancer and the likeli-
hood of concomitant systemic disease—5 of the 9 case reports hadextensive areas of necrosis (H&E, ×40). (B)Medium-power view showing tumor forming
High-power view showing highly pleomorphic tumor cells and one atypical tetra-polar
istochemical stain (CK7, ×200).
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36 T. Sierra et al. / Gynecologic Oncology Reports 11 (2015) 34–37systemic disease. Additionally, previous chemotherapy agents used
need to be considered, as metastatic lesions may be chemoresistant.
One agent with supporting data is topotecan, known to freely cross
the blood–brain barrier, with activity against lung cancer brainmetasta-
sis (Wong and Berkenblit, 2004; Langer and Mehta, 2005). Paclitaxel
has also been studied for brain metastasis, in combination with WBRT,
but it did not show an improvement in median survival (Glantz et al.,
1999).
The treatment outcomes for these patients are difﬁcult to interpret,
as the stage, extent of disease, and individual health must be taken
into consideration to judge success. However, the median survival
since diagnosis of brain metastasis was poor at 5 months, which is the
exact same ﬁnding that Piura et al. note in their review of 115 cases of
endometrial cancer (91 with available data). This suggests that perhaps
mortality is due to the presence of brain metastasis and overall disease
and not the histological type of cancer—although, again, with a small
case series no ﬁrm conclusions should be made. Piura et al. conclude
that longer survival results when multimodal therapy is used, such as
surgery/radiosurgery followed byWBRTwith orwithout chemotherapy
(22 months) versus WBRT alone (2 months) or craniotomy alone
(2.25 months). Our ﬁndings support this conclusion. Additionally, a
randomized trial showed that surgical resection plus radiotherapy
results in better survival and quality of life compared to radiotherapy
alone for solitary brain metastases (Patchell et al., 1990). Of note, this
study included 48 patients with Karnofsky performance scores N70%
and primary cancers from lung, breast, GI, GU, and melanoma. When
patient status is otherwise reassuring, especially in the presence of a
solitary lesion, we support multimodal therapy including surgical
resection.Conclusion
This is the ninth case report of USC brainmetastasis published in the
literature. Although it is an uncommon type of uterine carcinoma, this
case review suggests that USC resembles other endometrial cancers in
regard to its high-grade nature, interval to brain metastasis, survival,
and treatment outcomes. However, the scarcity of reported cases neces-
sitates highly individualized therapy, as there is no standard ofmanage-
ment. When appropriate, it seems that multimodal therapy offers the
best hope.Conﬂicts of interest statement
The authors report no conﬂict of interest.
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